Adverse events following Immunization with Sinopharm (Vero Cell) inactivated COVID-19 vaccine

Adverse events of Vero Cell vaccine

Abstract

Introduction: Various types of COVID 19 vaccines are being used globally to control the current pandemic. Post-licensure surveillance of vaccines is essential to ensure safety. This study aimed to determine Adverse Events Following Immunization (AEFIs) of Sinopharm (Vero cell), the inactivated COVID-19 vaccine from China.

Method: This is a cross-sectional observational study conducted at Patan hospital, Patan Academy of Health Sciences (PAHS). Vaccine recipients between April and May were contacted through a phone call after 72 h of vaccination to record the AEFIs. Pattern and distribution of AEFIs were analyzed. Ethical approval was taken from PAHS IRC.

Result: A total of 6142 individuals got the first dose of the vaccine and out of them we were able to contact 4574 through phone calls. Of the 4574, only 941 were included for the follow-up phone call after the second dose of the vaccine. A total of 1336 AEFIs were reported in 868(19%) first dose vaccine recipients while 147 AFEIs were reported in 105(11.2%) second dose vaccine recipients.  The frequently reported AEFIs were pain at the injection site, lethargy, headache, muscle ache, and fever. All the AEFIs were mild to moderate in severity. Most of the AEFIs started within 24 h and resolved within 72 h.

Conclusion: The Sinopharm (Vero cell) vaccine was found to have mild to moderate AEFIs in our study cohort and no case of severe AEFI was identified.